Effects of a selective ETA-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma:: demonstration of mouse strain specificity

被引:5
|
作者
Gosselin, M
Goulet, S
Wu-Wong, JYR
Wessale, JL
Opgennorth, TJ
Boulet, LP
Battistini, B
机构
[1] Hop Laval, Res Ctr, Quebec Heart & Lung Inst, St Foy, PQ G1V 4G5, Canada
[2] Abbott Labs, Div Pharmaceut Prod, Dis Res Drug Discovery, Abbott Pk, IL 60064 USA
关键词
Balb/c mouse; C57Bl/6; mouse; endothelin A receptor antagonist; atrasentan;
D O I
10.1042/CS103S367S
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Asthma is a chronic respiratory disease that is characterized by airway inflammation, bronchoconstriction and the influx of pro-inflammatory cells, mostly eosinophils in the lung tissue and bronchoalveolar space. Amongst the many physiopathological roles attributed to endothelins (ETs), one is to modulate pulmonary functions. It is established that Balb/c mice develop allergen-induced Th-2-cytokine gene expression, airway inflammation and hyper-responsiveness whereas C57B1/6 mice are much less reactive. In the present study, we investigated the roles of ETs in these two murine models of allergic asthma (AA). Mice were sensitized and challenged with either saline (S) and/or ovalbumin (0) over 6 weeks (groups S/S and O/O) and treated chronically with ABT-627 or its vehicle. Twenty-four hours after the last sensitization, challenged mice developed a marked airway inflammatory response characterized by the accumulation of total inflammatory cells (a 21-fold increase) in the bronchoalveolar space, similar in both mouse strains. The increase in eosinophils was marked in both groups, representing 98% of total cell count in O/O versus <1% in S/S. Macrophages were also increased 3-fold in both strains. ABT-627 did reduce the accumulation of macrophages in both stains (36 to 53%) whereas it blocked by 76% the influx of eosinophils in Balb/c but not in C57B1/6 mice. These results show that ETA-receptor antagonism is more effective against O/O-induced AA in Balb/c mice, even though both strains were associated with the same increase in key pro-inflammatory cells in the bronchoalveolar space. It is unclear whether this is due to a lack or a disproportionate expression of ETA receptors in these two murine strains, or in post-receptor transduction modulation, or different regulation of ET receptors in various pulmonary cells, after sensitization and challenge.
引用
收藏
页码:367S / 370S
页数:4
相关论文
共 5 条
  • [1] Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans
    Verhaar, MC
    Grahn, AY
    van Weerdt, AWM
    Honing, MLH
    Morrison, PJ
    Yang, YHP
    Padley, RJ
    Rabelink, TJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (06) : 562 - 573
  • [2] Selective ETA receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans
    Honing, MLH
    Hijmering, ML
    Ballard, DE
    Yang, YHP
    Padley, RJ
    Morrison, PJ
    Rabelink, TJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2000, 11 (08): : 1498 - 1504
  • [3] ABT-627, an endothelin ETA receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain
    Jarvis, MF
    Wessale, JL
    Zhu, CZ
    Lynch, JJ
    Dayton, BD
    Calzadilla, SV
    Padley, RJ
    Opgenorth, TJ
    Kowaluk, EA
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 388 (01) : 29 - 35
  • [4] Effects of a selective endothelin A receptor antagonist, ABT-627, in healthy normotensive anaesthetized rats developing acute pulmonary air embolism
    Ayach, B
    Tsang, J
    Jeng, AY
    Blouin, A
    Gosselin, M
    Wang, FH
    Wu-Wong, JYR
    Wessale, J
    Opgenorth, TJ
    Battistini, B
    CLINICAL SCIENCE, 2002, 103 : 371S - 375S
  • [5] Effect of ABT-627 (A-147627), a potent selective ETA receptor antagonist, on the cardiopulmonary profile of newborn lambs with surgically-induced diaphragmatic hernia
    Kavanagh, M
    Battistini, B
    Jean, S
    Crochetière, J
    Fournier, L
    Wessale, J
    Opgenorth, TJ
    Cloutier, R
    Major, D
    BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (08) : 1679 - 1688